A ScienceDaily report has revealed that the common diabetes drug metformin acts partly in the brain to reduce blood sugar levels, a mechanism hidden for six decades since its introduction. According to the release, metformin switches off a key protein and activates specific neurons, triggering this central nervous system pathway that complements its known effects in the body. This could open new avenues for more targeted diabetes therapies.

The content is based on a news release from ScienceDaily (https://www.sciencedaily.com/releases/2026/03/260325055441.htm) summarizing the research. However, the release provides no details on study methodology, such as experimental models used (e.g., rodents or cell cultures), sample sizes, controls, or statistical methods. It also does not discuss limitations, such as whether findings are limited to animals and not yet confirmed in humans. The release does not specify if the underlying work is a preprint or peer-reviewed publication, though ScienceDaily most often covers published journal articles.

This discovery indicates metformin has dual sites of action, with the newly identified brain route contributing to its glucose-lowering benefits. Researchers suggest the finding may lead to redesigned drugs that more precisely engage this neural pathway while minimizing side effects.